A notable example is the sequential use of Pexa-Vec (JX-594) followed by sorafenib in HCC, where Pexa-Vec primes the tumor for VEGF/VEGFR inhibition, enhancing sorafenib efficacy (184, 185). The gene discussed is VEGFA; the disease is neoplasm.